1,3-BIS(ISOCYANATOMETHYL)CYCLOHEXANE | CAS:38661-72-2

We serve 1,3-BIS(ISOCYANATOMETHYL)CYCLOHEXANE CAS:38661-72-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1,3-BIS(ISOCYANATOMETHYL)CYCLOHEXANE

Chemical Name:1,3-BIS(ISOCYANATOMETHYL)CYCLOHEXANE
CAS.NO:38661-72-2
Synonyms:1,3-BIS(ISOCYANATOMETHYL)CYCLOHEXANE
1,3-diisocyanatomethylcyclohexane
1,3-cyclohexanedimethane diisocyanate
1,3-bisisocyanatomethyl cyclohexane
1,3-Bis(isocyanatomethyl)cyclohexane
 
Physical and Chemical Properties:
Density 1.14 g/cm3
Boiling Point 294.4ºC at 760 mmHg
Molecular Formula C10H14N2O2
Molecular Weight 194.23000
Flash Point 119.5ºC
 
Specification:
Appearance:Colorless liquid
Assay:≥99.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 1,3-BIS(ISOCYANATOMETHYL)CYCLOHEXANE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,3-Bis(isocyanatomethyl)cyclohexane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,3-Bis(isocyanatomethyl)cyclohexane Use and application,1,3-bisisocyanatomethyl cyclohexane technical grade,usp/ep/jp grade.


Related News: But several border points remain open, and many medical workers fear that Hong Kong’s well-regarded health care system will be overwhelmed.6-Iodo-1-hexanol acetate manufacturer The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace.Pyridinium Tribromide supplier Three more patients have been confirmed infected with coronavirus in South Korea, bringing the country’s total to 15, the South Korean Centers for Disease Control and Prevention (KCDC) announced in a press release.O-(2-MethoxyEthoxy)BenzeneSulfonamide vendor However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.“We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”